Rezpegaldesleukin is a recombinant protein commercialized by Nektar Therapeutics, with a leading Phase II program in Systemic Lupus Erythematosus. According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 2 are ongoing, 5 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Rezpegaldesleukin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Rezpegaldesleukin is expected to reach an annual total of $8 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Rezpegaldesleukin Overview

NKTR-358 is under development for the treatment of immunological disorders including systemic lupus erythematosus (SLE), atopic dermatitis and plaque psoriasis. It is a recombinant protein administered through subcutaneous route.  It acts by targeting interleukin 2 receptor subunit alpha and gamma.

It was also under development for the treatment of ulcerative colitis.

Nektar Therapeutics Overview

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology, among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

The company reported revenues of (US Dollars) US$101.9 million for the fiscal year ended December 2021 (FY2021), a decrease of 33.4% over FY2020. The operating loss of the company was US$446.1 million in FY2021, compared to an operating loss of US$425.1 million in FY2020. The net loss of the company was US$523.8 million in FY2021, compared to a net loss of US$444.4 million in FY2020. The company reported revenues of US$23.6 million for the third quarter ended September 2022, an increase of 9.5% over the previous quarter.

For a complete picture of Rezpegaldesleukin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.